We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...

For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. | For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. While it ...

Provide specific products and services to you, such as portfolio management or data aggregation. Develop and improve features of our offerings. Gear advertisements and other marketing efforts ...

The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...

The quarter saw strong performance across key product portfolios. Flagship brands within the general medicines portfolio ... Managing Director of GlaxoSmithKline Pharmaceuticals Limited, said ...

UK drugmaker GSK is struggling to convince the market ... for GSK is to persuade investors it can rebuild its oncology portfolio, after leaving the market in 2015. It subsequently went back ...

In this article, in addition to analyzing GSK's financial results for Q4 2024, I also presented an analysis of the most interesting developments in its portfolio. However, that's not all.

Most of this spent is out of the pocket. By providing a big portfolio of 140 products with a relative low price, GSK is winning the game of "volume" in the market. This large portfolio also gives ...

And should I consider adding GSK to my portfolio? The first thing I’ll ... given the huge costs associated with product development. Once again GSK looks good, with its net debt falling to ...

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

Royalty Pharma’s portfolio includes market-leading ... royalty receipt by less than 0.5%. Among other products, we anticipate GSK’s Trelegy to be on the future list of Medicare negotiations ...

The addition of Chimerix’s drug could help Jazz expand its oncology portfolio and further diversify ... will be determined in further proceedings. GSK plc announced that the FDA accepted its ...